Trial Profile
Double-blind, Randomized, Placebo-controlled, Parallel Group and Dose-finding, Multicentric, Safety and Efficacy Study With Intramuscular Injections of NV1FGF in Subjects With Intermittent Claudication.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Riferminogene pecaplasmide (Primary)
- Indications Intermittent claudication
- Focus Therapeutic Use
- 14 Jul 2010 New trial record